Burns, J. C., Roberts, S. C., Tremoulet, A. H., He, F., Printz, B. F., Ashouri, N., Jain, S. S., Michalik, D. E., Sharma, K., Truong, D. T., Wood, J. B., Kim, K. K., Jain, S., , , Anand, V., Anderson, M., Ang, J., Ansusinha, E., Arditi, M., Bartlett, A., Baker, A., Chatterjee, A., DeBiasi, R., De Ferranti, S., Dekker, C., DeZure, C., Dominguez, S., Erdem, G., Halasa, N., Harahsheh, A. S., Hite, M., Jaggi, P., Jone, P., Jones, J., Kaushik, N., Kumar, M., Kurio, G., Lloyd, D., Manaloor, J., McNelis, A., Nadipuram, S., Newburger, J., Newcomer, C., Perkins, T., Portman, M., Romero, J. R., Rometo, A., Ronis, T., Rosenkranz, M., Rowley, A., Samuy, N., Scalici, P., Schuster, J., Sexson Tejtel, S. K., Simonsen, K., Szmuszkovicz, J., & Yeh, S. (2021). infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial. Lancet, 5, 852–861. http://access.bl.uk/ark:/81055/vdc_100146097784.0x00000c